Literature DB >> 23428214

Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes.

Masoor Kamalesh1, Thomas G Sharp, X Charlene Tang, Kendrick Shunk, Herbert B Ward, James Walsh, Spencer King, Cindy Colling, Thomas Moritz, Kevin Stroupe, Domenic Reda.   

Abstract

OBJECTIVES: This study sought to determine the optimal coronary revascularization strategy in patients with diabetes with severe coronary disease.
BACKGROUND: Although subgroup analyses from large trials, databases, and meta-analyses have found better survival for patients with diabetes with complex coronary artery disease when treated with surgery, a randomized trial comparing interventions exclusively with drug-eluting stents and surgery in patients with diabetes with high-risk coronary artery disease has not yet been reported.
METHODS: In a prospective, multicenter study, 198 eligible patients with diabetes with severe coronary artery disease were randomly assigned to either coronary artery bypass grafting (CABG) (n = 97) or percutaneous coronary intervention (PCI) with drug-eluting stents (n = 101) and followed for at least 2 years. The primary outcome measure was a composite of nonfatal myocardial infarction or death. Secondary outcome measures included all-cause mortality, cardiac mortality, nonfatal myocardial infarction, and stroke.
RESULTS: The study was stopped because of slow recruitment after enrolling only 25% of the intended sample size, leaving it severely underpowered for the primary composite endpoint of death plus nonfatal myocardial infarction (hazard ratio: 0.89; 95% confidence interval: 0.47 to 1.71). However, after a mean follow-up period of 2 years, all-cause mortality was 5.0% for CABG and 21% for PCI (hazard ratio: 0.30; 95% confidence interval: 0.11 to 0.80), while the risk for nonfatal myocardial infarction was 15% for CABG and 6.2% for PCI (hazard ratio: 3.32; 95% confidence interval: 1.07 to 10.30).
CONCLUSIONS: This study was severely underpowered for its primary endpoint, and therefore no firm conclusions about the comparative effectiveness of CABG and PCI are possible. There were interesting differences in the components of the primary endpoint. However, the confidence intervals are very large, and the findings must be viewed as hypothesis generating only. (Coronary Artery Revascularization in Diabetes; NCT00326196).
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23428214     DOI: 10.1016/j.jacc.2012.11.044

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

Review 1.  Comparison of percutaneous coronary intervention with drug eluting stents versus coronary artery bypass grafting in patients with multivessel coronary artery disease: Meta-analysis of six randomized controlled trials.

Authors:  Zaher Fanari; Sandra A Weiss; Wei Zhang; Seema S Sonnad; William S Weintraub
Journal:  Cardiovasc Revasc Med       Date:  2015-01-22

Review 2.  Bypass grafting versus percutaneous intervention in multivessel coronary disease: the current state.

Authors:  Ilke Sipahi
Journal:  Curr Cardiol Rep       Date:  2015-02       Impact factor: 2.931

3.  Comparison of coronary artery bypass graft surgery and percutaneous coronary intervention in patients with diabetes.

Authors:  Bora Toklu; Sripal Bangalore
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-05

4.  Coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease: quo vadis? -a review of the evidences on coronary artery disease.

Authors:  Cristiano Spadaccio; Umberto Benedetto
Journal:  Ann Cardiothorac Surg       Date:  2018-07

5.  Challenges in Patients with Diabetes: Improving Clinical Outcomes After Percutaneous Coronary Intervention Through EVOlving Stent Technology.

Authors:  Robert A Byrne; Shmuel Banai; Roisin Colleran; Antonio Colombo
Journal:  Interv Cardiol       Date:  2018-01

6.  Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study.

Authors:  Michael E Farkouh; Michael Domanski; George D Dangas; Lucas C Godoy; Michael J Mack; Flora S Siami; Taye H Hamza; Binita Shah; Giulio G Stefanini; Mandeep S Sidhu; Jean-François Tanguay; Krishnan Ramanathan; Samin K Sharma; John French; Whady Hueb; David J Cohen; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2018-11-11       Impact factor: 24.094

Review 7.  Revascularization for Advanced Coronary Artery Disease in Type 2 Diabetic Patients: Choosing Wisely Between PCI and Surgery.

Authors:  Louai Razzouk; Frederick Feit; Michael E Farkouh
Journal:  Curr Cardiol Rep       Date:  2017-05       Impact factor: 2.931

8.  [Percutaneous coronary intervention versus bypass surgery in patients with diabetes and multivessel coronary disease. Coronary revascularization after FREEDOM].

Authors:  R Dörr; J Stumpf; J Dalibor; G Simonis; S G Spitzer
Journal:  Herz       Date:  2014-05       Impact factor: 1.443

Review 9.  Percutaneous coronary intervention in patients with diabetes: current concepts and future directions.

Authors:  Ehrin J Armstrong; Johannes Waltenberger; Jason H Rogers
Journal:  J Diabetes Sci Technol       Date:  2014-02-05

Review 10.  Comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: a meta-analysis.

Authors:  Xuebiao Li; Minjian Kong; Daming Jiang; Aiqiang Dong
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.